From the Department of Anaesthesia, University Hospital Rostock, Germany (JPR, GEFNS, TWLS); Department of General Dermatology, Division of General Dermatology, Medical University of Vienna, Austria (PP); Molecular Cardioprotection & Inflammation Group, Department of Anaesthesia, University Hospital Bristol, Bristol Royal Infirmary, United Kingdom (AK, PAZ, KZ); Molecular Cardioprotection & Inflammation Group, Department of Anaesthesia, University Hospital Dusseldorf, Germany (JM, OB, KZ); Fibrex Medical Inc., Vienna, Austria (SR, WB); Pharm-analyt Lab GmbH, Baden, Austria (DM); Department of Clinical Pharmacology, Medical University of Vienna, Austria (MW); and Department of Clinical Chemistry, University Hospital Dusseldorf, Germany (CB).
Supported, in part, by a research grant from Fibrex Medical Research & Development GmbH, Vienna, Austria.
Dr. Petzelbauer receives consultancy fees and owns shares of Fibrex Medical Inc. Dr. Reingruber owns shares of Fibrex Medical Inc. Dr. Zacharowski receives consultancy fees and owns stock options of Fibrex Medical Inc. The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: [email protected] or [email protected]